{"entity":{"id":"nct04906395","kind":"trial","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","aka":[],"tldr":"A phase 3 trial of Tamoxifen and Exemestane in advanced solid tumours, run by Tolmar Inc., active and no longer recruiting.","summary":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer is a phase 3 interventional study registered as NCT04906395 by Tolmar Inc., with 250 participants enrolled, started 2021-07-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets and Exemestane Tablets.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04906395","url":"https://clinicaltrials.gov/study/NCT04906395"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tamoxifen","exemestane"],"companies":["tolmar"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04906395","phase":"3","setting":"Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","sponsor":"Tolmar Inc.","enrolled":250,"outcomes":[]},"route":"/trials/nct04906395/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"company":[{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/"}]}}